BRPI0507776A - métodos de modular a atividade de citocina; reagentes relacionados - Google Patents

métodos de modular a atividade de citocina; reagentes relacionados

Info

Publication number
BRPI0507776A
BRPI0507776A BRPI0507776-1A BRPI0507776A BRPI0507776A BR PI0507776 A BRPI0507776 A BR PI0507776A BR PI0507776 A BRPI0507776 A BR PI0507776A BR PI0507776 A BRPI0507776 A BR PI0507776A
Authority
BR
Brazil
Prior art keywords
methods
cytokine activity
related reagents
modulating cytokine
modulating
Prior art date
Application number
BRPI0507776-1A
Other languages
English (en)
Inventor
Robert A Kastelein
Terrill K Mcclanahan
Stefan Pflanz
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34886193&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0507776(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of BRPI0507776A publication Critical patent/BRPI0507776A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"MéTODO FR MODULAR A TIVIDADE DE CITOCINA;REAGENTES RELACIONADOS" Fornecidos são métodos para modular a atividade de citocina, por exemplo,com o propósito de tratar distúrbios inflamatórios e imunes. Também fornecidos são métodos de administração dos agonistas ou antagonistas do receptor de IL-27 e IL- 27.
BRPI0507776-1A 2004-02-17 2005-02-15 métodos de modular a atividade de citocina; reagentes relacionados BRPI0507776A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54576204P 2004-02-17 2004-02-17
PCT/US2005/004902 WO2005079848A2 (en) 2004-02-17 2005-02-15 Agonists and antagonists of p28 ebi3 and wsx/tccr for treating immune disorders

Publications (1)

Publication Number Publication Date
BRPI0507776A true BRPI0507776A (pt) 2007-07-10

Family

ID=34886193

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507776-1A BRPI0507776A (pt) 2004-02-17 2005-02-15 métodos de modular a atividade de citocina; reagentes relacionados

Country Status (11)

Country Link
US (1) US20050214296A1 (pt)
EP (1) EP1755641A2 (pt)
JP (1) JP2007523169A (pt)
CN (1) CN1921886A (pt)
AU (1) AU2005215771A1 (pt)
BR (1) BRPI0507776A (pt)
CA (1) CA2555421A1 (pt)
NO (1) NO20064192L (pt)
TW (1) TW200531679A (pt)
WO (1) WO2005079848A2 (pt)
ZA (1) ZA200606833B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004069173A2 (en) 2003-01-31 2004-08-19 The Trustees Of The University Of Pennsylvania Methods for modulating an inflammatory response
WO2008011081A2 (en) * 2006-07-19 2008-01-24 The Trustees Of The University Of Pennsylvania Wsx-1/p28 as a target for anti-inflammatory responses
WO2008025033A2 (en) * 2006-08-25 2008-02-28 Zymogenetics, Inc. Use of il-27 antagonists for the manufacture of a medicament for the treatment of aplastic anemia
US8784807B2 (en) * 2006-09-22 2014-07-22 St. Jude Children's Research Hospital Method of inhibiting regulatory T-cell activity by administering an antibody that inhibits interleukin 35
WO2009052487A2 (en) * 2007-10-18 2009-04-23 University Of South Florida Method of detecting oncogenesis of hematopoietic cells
WO2010065116A2 (en) * 2008-12-02 2010-06-10 The Trustees Of The University Of Pennsylvania The use of il-27-p28 to antagonize il-6 mediated signaling
US20100297127A1 (en) * 2009-04-08 2010-11-25 Ghilardi Nico P Use of il-27 antagonists to treat lupus
AU2010298036B2 (en) 2009-09-25 2015-05-21 Xoma Technology Ltd. Screening methods
JP5669055B2 (ja) * 2009-10-27 2015-02-12 国立大学法人佐賀大学 ダブルノックアウト非ヒト動物
JP5822248B2 (ja) * 2009-10-27 2015-11-24 国立大学法人佐賀大学 ノックアウト非ヒト動物
US20130183326A9 (en) 2009-11-20 2013-07-18 St. Jude Children's Research Hospital Methods and compositions for modulating the activity of the interleukin-35 receptor complex
WO2011133931A1 (en) * 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
CN102337268B (zh) * 2010-07-16 2013-04-24 北京大学 人类ctrp4基因、其编码的蛋白质及它们的应用
AU2012205384B2 (en) * 2011-01-14 2015-09-10 Five Prime Therapeutics, Inc. IL-27 antagonists for treating inflammatory diseases
JP6083784B2 (ja) * 2012-07-02 2017-02-22 国立研究開発法人理化学研究所 慢性閉塞性肺疾患の増悪指標の検出方法
CN102816794A (zh) * 2012-08-23 2012-12-12 南开大学 一种鼠源il-27重组蛋白真核表达载体及构建方法
US20150284459A1 (en) * 2012-10-31 2015-10-08 The Brigham And Women's Hospital, Inc. Methods for modulating immune responses during chronic immune conditions by targeting il-27 induced pathways
JP6187985B2 (ja) * 2015-07-14 2017-08-30 国立大学法人佐賀大学 ノックアウト非ヒト動物
CN120173101A (zh) * 2018-03-22 2025-06-20 表面肿瘤学有限责任公司 抗il-27抗体及其用途
SG11202105161YA (en) 2018-12-13 2021-06-29 Surface Oncology Inc Anti-il-27 antibodies and uses thereof
CN110305864A (zh) * 2019-07-05 2019-10-08 山东省寄生虫病防治研究所 一种用于干扰DNALI1基因表达的siRNA及其在抑制细胞增殖和迁移中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744301A (en) * 1992-11-25 1998-04-28 Brigham And Women's Hospital Methods of detection of epstein barr virus induced genes expressed in the placenta
WO1997013859A1 (en) * 1995-10-11 1997-04-17 Brigham And Women's Hospital, Inc. A novel haematopoietic cytokine and uses therefor
DE69734443T2 (de) * 1996-01-08 2006-07-13 Genentech, Inc., South San Francisco Ob-rezeptor und liganden
US5874252A (en) * 1997-07-29 1999-02-23 Smithkline Beecham Corporation Splicing variant of the Epstein-Barr virus-induced G-protein coupled receptor
ATE440953T1 (de) * 1999-07-30 2009-09-15 Schering Corp Cytokine aus säugetieren und dazugehírende reagenzien
US7148330B2 (en) * 1999-07-30 2006-12-12 Schering Corporation Binding compounds for IL-27
US20030008343A1 (en) * 1999-07-30 2003-01-09 Timans Jacqueline C Mammalian cytokines; related reagents
BR0015055A (pt) * 1999-10-20 2002-07-16 Genentech Inc Método de aumento estimulação ou potencialização da diferenciação de células t, método de tratamento de uma doença mediada por th1 em um mamìfero, método de prevenir, inibir ou atenuar a diferenciação de céluas t, método de tratamento de uma doença mediada por th2, em um mamìfero, método de determinação da presença de polipeptìdeo tccr em uma célula, método de diagnóstico de doenças mediadas por th1 ou mediadas por th2 em um mamìfero, método de identificação de compostos capazes de inibir a expressão de polipeptìdeos tccr e método para identificação de compostos capazes de inibir a atividade biológica de polipeptìdeo tccr, uso de antagonistas e agonistas de polipeptìdeos tccr
US7086337B2 (en) * 2000-09-28 2006-08-08 Klein John M Non-lethal projectile ammunition
ATE506987T1 (de) * 2002-12-31 2011-05-15 Schering Corp Il-27 et il-2 pour le traitement du cancer

Also Published As

Publication number Publication date
CA2555421A1 (en) 2005-09-01
TW200531679A (en) 2005-10-01
EP1755641A2 (en) 2007-02-28
US20050214296A1 (en) 2005-09-29
ZA200606833B (en) 2008-05-28
AU2005215771A1 (en) 2005-09-01
NO20064192L (no) 2006-11-16
WO2005079848A3 (en) 2005-12-15
WO2005079848A9 (en) 2006-12-07
WO2005079848A2 (en) 2005-09-01
CN1921886A (zh) 2007-02-28
JP2007523169A (ja) 2007-08-16

Similar Documents

Publication Publication Date Title
BRPI0507776A (pt) métodos de modular a atividade de citocina; reagentes relacionados
BRPI0507808A (pt) métodos de modular a atividade de citocina; reagentes relacionados
BR0309875A (pt) métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto
BR0207775A (pt) Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
ATE556713T1 (de) Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
ECSP056027A (es) Tratar desorden inmunológico usando agonistas de interleucina - 21/receptor de interleucina - 21.
CY1109521T1 (el) Μεθοδοι ρυθμισης υποδοχεων cd200
PT1042305E (pt) Inibicao de quinase p38 utilizando difenilureias simetricas e assimetricas
BRPI0307351B8 (pt) composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
AU2002345497A1 (en) Cips as modifiers of the p53 pathway and method of use
BRPI0507794A (pt) métodos de modular a atividade de il-23, reagentes relacionados
EP1140840A4 (en) -G (V) -CARBOXYARYL SUBSTITUTED DIPHENYL UREASINE AS RAF KINASE INHIBITORS
BRPI0408247A (pt) usos de antagonistas e agonistas de il-23 e reagentes relacionados
ES2151467T1 (es) Inhibicion de la actividad de la quinasa p38 por aril-ureas.
ATE447561T1 (de) Substituierte aryl 1,4-pyrazin derivate
DE60336901D1 (de) Chinazolinon modulatoren von nukleinrezeptoren
EP1389209A4 (en) FOLAT MIMETICS AND THEIR FOLAT RECEPTOR BINDING CONJUGATES
WO2004060291A3 (en) Uses of mammalian cytokine; related reagents
BR0311443A (pt) Método e dispositivo para controlar farmacocinética de droga
EP1809280A4 (en) MITOTIC KINESINE INHIBITORS AND METHOD OF USE THEREOF
WO2003065985A3 (en) Uses of mammalian cytokine; related reagents
SE0202598D0 (sv) Alpha-7 Nicotinic receptor agonists and statins in combination
BRPI0410807A (pt) composição farmacêutica, e, método pata tratar um mamìfero sofrendo de ou susceptìvel a condições associadas com dor cefálica
DK0556322T3 (da) Aminosulfonylurinstof-ACAT-inhibitorer

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]